Results

1–10 of 38 results for real-world

Safety Profiles of Combined Anticomplement and Anti-VEGF Intravitreal Therapies for Age-Related MacularDegeneration From Real-World Data
Edward H. Wood, MD, FASRS
Annual Meeting Talks
2025
Early Insights From Real-World Use of Aflibercept 8 mg Among Eyes With Diabetic Macular Edema SwitchingFrom Other Anti-VEGF Agents
Michael Javaheri, MD
Annual Meeting Talks
2025
Durability and Safety of Suprachoroidal Triamcinolone Acetonide in Eyes with Chronic Cystoid Macular Edema in Real-world Clinical Practice
Sunir J. Garg, MD, FACS, FASRS
Updates from the Field
2026
Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Emmanuel Chang, MD PhD FACS FASRS
Annual Meeting Talks
2023
Bevacizumab-First vs Real-World Cost Outcomes for Diabetic Macular Edema: 2-Year Cost Analysis Modeled on DRCR Protocol AC Results
Dilraj S Grewal, MD, FASRS
Annual Meeting Talks
2023
Expert Panel: Socioeconomics
Linda A. Lam, MD, MBA, FASRS
Ella H Leung, MD
Mohsin H. Ali, MD
Hasenin Al-khersan, MD
Miguel A. Busquets, MD, FACS
Annual Meeting Talks
2024
Expert Panel: AI
Mark S. Humayun, MD, PhD
Devinder S Chauhan, MD FRCOphth FRANZCO
Ursula M. Schmidt-Erfurth, MD
Jennifer I. Lim, MD, FARVO, FASRS
Royce WS Chen, MD
Annual Meeting Talks
2024
Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Annual Meeting Talks
2024
Real-World Intraoperative Surgical Parameters in the Eyetelligence Cloud: A National Surgical Database of US Vitreoretinal Surgeons
Prethy Rao, MD, MPH
Annual Meeting Talks
2024
12-Month Real-World Clinical and Anatomic Outcomes With Faricimab in Patients With Diabetic Macular Edema: The FARETINA-DME Study
Theodore Leng, MD, MS, FASRS
Annual Meeting Talks
2024